Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SAT1 | P21673 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250764 | 1.00 | CYP2C19 (0.55) | CYP2C19MEN1GLAKMT2ASAT1 | |
| SCHEMBL15884114 | 1.00 | CYP2C19 (0.55) | CYP2C19MEN1GLAKMT2ASAT1 | |
| Hydrochloric Acid SCHEMBL7563057 | 0.98 | CYP2C19 (0.52) | CYP2C19MEN1GLAKMT2ASAT1 | |
| Hydrochloric Acid SCHEMBL7563067 | 0.98 | CYP2C19 (0.52) | CYP2C19MEN1GLAKMT2ASAT1 | |
| Hydrochloric Acid SCHEMBL5963043 | 0.93 | GNAI3 (0.50) | CYP2C19MEN1GLAKMT2ASAT1 | |
| Hydrochloric Acid SCHEMBL5963045 | 0.93 | GNAI3 (0.50) | CYP2C19MEN1GLAKMT2ASAT1 | |
| SCHEMBL20052077 | 0.89 | CXCR4 (0.58) | CYP2C19MEN1GLAKMT2ASAT1 | |
| SCHEMBL8852124 | 0.86 | GNAI3 (0.62) | CYP2C19MEN1GLAKMT2ASAT1 | |
| SCHEMBL8852122 | 0.86 | SAT1 (0.46) | CYP2C19MEN1GLAKMT2ASAT1 | |
| SCHEMBL18236766 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113455-A1 | Method and composition for amelioration of pain | UNIVERSITY OF FLORIDA | 2005-05-26 | — | — | US | claimed |
| WO-2005041988-A1 | METHOD AND COMPOSITION FOR PAIN AMELIORATION | UNIVERSITY OF FLORIDA (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050113455-A1 | Method and composition for amelioration of pain | UNIVERSITY OF FLORIDA | 2005-05-26 | — | — | US | disclosed |
| WO-2005041988-A1 | METHOD AND COMPOSITION FOR PAIN AMELIORATION | UNIVERSITY OF FLORIDA (US) | 2005-05-12 | — | — | WO | disclosed |
| US-6818656-B2 | ADMINISTERING POLYAMINE TO TREAT DIARRHEA | UNIVERSITY OF FLORIDA | 2004-11-16 | — | — | US | disclosed |
| US-20040072864-A1 | Method and composition for treatment of irritable bowel disease | BERGERON RAYMOND J (US) | 2004-04-15 | — | — | US | disclosed |
| US-6664270-B2 | Utilizing small amounts of at least two polyamines; long term, safe, efficacious | UNIVERSITY OF FLORIDA | 2003-12-16 | — | — | US | disclosed |
| US-20030153582-A1 | Method and composition for treatment of irritable bowel disease | FLORIDA, UNIVERSITY OF | 2003-08-14 | — | — | US | disclosed |
| US-6458795-B1 | A METHOD AND COMPOSITION FOR TREATING IRRITABLE BOWEL SYNDROME IN A SUBJECT IN NEED OF SUCH TREATMENT, UTILIZING AN AMOUNT OF A POLYAMINE OR POLYAMINE WITH AN ETHER | UNIVERSITY OF FLORIDA | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153582-A1 | Method and composition for treatment of irritable bowel disease | HRH2, HRH4, HRH3 | CYP2C19 2295/4885MEN1 4339/4885GLA 4774/4885 |
| US-20040072864-A1 | Method and composition for treatment of irritable bowel disease | HRH2, HRH4, HRH3 | CYP2C19 2295/4885MEN1 4339/4885GLA 4774/4885 |
| US-20050113455-A1 | Method and composition for amelioration of pain | SIGMAR1, ADORA2B, OPRL1 | CYP2C19 2079/4885MEN1 2057/4885GLA 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.